Dermira has generated evidence that its treatment for moderate-to-severe atopic dermatitis can pose a challenge to Regeneron and Sanofi’s Dupixent.
Shares in Aerpio Pharmaceuticals were more than halved in early trading this morning after it announced the failure of its leading drug candidate.
The series B sets Imara up to wrap up a phase 2a trial of a phosphodiesterase-9 inhibitor it picked up from Lundbeck and push deeper into the clinic.
Boston startup Karuna Therapeutics has raised a chunky $68 million as it looks to beef up work on its Alzheimer’s/schizophrenia combo therapy.
Novartis’ Alcon unit is picking up 2016 Fierce 15 company PowerVision in a $285 million deal for its flexible, fluid-based intraocular lens.
Allergy Therapeutics saw its stock down 40% in early trading in London after its birch pollen drug failed to move the needle in a key phase 3 trial.
The FDA will evaluate the state of the science around medical device materials, with subsets of patients developing painful responses to implants.
ExcepGen believes its approach could speed up discovery and even come up with protein targets previously thought to be undruggable.
Stryker has acquired OrthoSpace, developers of a therapy for severely torn rotator cuffs, in a deal worth up to $220 million.
Ortho received a CE mark for its new multitest platform that allows laboratories to run two in vitro diagnostic tests simultaneously on one slide.